A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD


The phase 2 study will evaluate the safety, tolerability and efficacy of HLD100 at steady state (following up to 5 weeks of treatment) in children using an outpatient, single-center, open-label, flexible dose-escalation study design.

Full Title of Study: “Phase II, Open-label, Dose-titration, Safety Study Designed to Determine the Evening Dose of a Novel Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) to Produce Optimal Clinical Effects in Children With ADHD”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 18, 2016

Detailed Description

This dose-escalation study will examine HLD100 in 24 subjects. The subjects (n=24) will be tested with HLD100 in ascending doses from 10mg up to 40mg. This study will be divided into several phases: Screening, Active Treatment and Follow-Up. All visits have a 2 day window to allow for scheduling.


  • Drug: HLD100
    • Treatment

Arms, Groups and Cohorts

  • Experimental: HLD100 10mg
    • HLD100 (dextroamphetamine sulfate) DR/ER capsules (10mg)
  • Experimental: HLD100 20mg
    • HLD100 (dextroamphetamine sulfate) DR/ER capsules (20mg)
  • Experimental: HLD100 30mg
    • HLD100 (dextroamphetamine sulfate) DR/ER capsules (30mg)
  • Experimental: HLD100 40mg
    • HLD100 (dextroamphetamine sulfate) DR/ER capsules (40mg)

Clinical Trial Outcome Measures

Primary Measures

  • Dose Escalation to determine optimal dosage for clinical effects
    • Time Frame: 6 weeks
    • Primary outcome is the determination of the dose achieving optimal clinical effect in a safe and tolerable manner

Secondary Measures

  • Safety (AEs, ECG, laboratory parameters, physical examinations)
    • Time Frame: 48 hours
    • Safety endpoints include treatment-emergent adverse events (TEAEs), vital signs, electrocardiogram (ECG) parameters, physical examination, and the C-SSRS.

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects must have a diagnosis of ADHD as defined by DSM-5 criteria with confirmation using the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). – Subjects must demonstrate mild-to-moderate impairment of ADHD symptoms and function per the following at screening (V1) and/or baseline (V2): – ADHD-RS-IV score at or above the 90th percentile normalized for sex and age in total score and ≥24 at Baseline; – CGI-S score ≥4; – Subject body weight must be ≥20 kg. – Subject must be considered clinically appropriate for treatment with amphetamine and HLD100, including prior treatment experience with an amphetamine product, and ability to swallow treatment capsules. Exclusion Criteria:

  • History of, or current, medical condition or laboratory result which, in the opinion of the investigator, unfavorably alters the risk-benefit of study participation, may jeopardize subject safety, or may interfere with the satisfactory completion of the study and study-related procedures. – Serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other cardiac problems that may place the subject at increased vulnerability to the sympathomimetic effects of a stimulant drug. – History of seizure disorder (except febrile seizures prior to age 5 and with last occurrence at least 1 year prior to study participation), Tourette's disorder, or intellectual disability of minor severity or greater (DSM-5 criteria). – History of psychosis, bipolar disorder, anorexia nervosa, bulimia, or suicide attempt. Current depression, anxiety, conduct/behavior disorder, substance use disorder, or other psychiatric condition which, in the investigator's opinion, may jeopardize subject safety or may interfere with the satisfactory completion of the study and study-related procedures. – Active suicidal ideation as evidenced by an ideation score of 2 or greater on the C-SSRS. – History of severe allergic reaction or intolerance to amphetamine.

Gender Eligibility: All

Minimum Age: 6 Years

Maximum Age: 12 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ironshore Pharmaceuticals and Development, Inc
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Ann Childress, MD, Principal Investigator, Center for Psychiatry & Behavoural Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.